BR112019002734A2 - tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart - Google Patents

tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart

Info

Publication number
BR112019002734A2
BR112019002734A2 BR112019002734-3A BR112019002734A BR112019002734A2 BR 112019002734 A2 BR112019002734 A2 BR 112019002734A2 BR 112019002734 A BR112019002734 A BR 112019002734A BR 112019002734 A2 BR112019002734 A2 BR 112019002734A2
Authority
BR
Brazil
Prior art keywords
treatment
hiv infection
antibodies
haart
sustained virological
Prior art date
Application number
BR112019002734-3A
Other languages
English (en)
Inventor
Yi Wang Chang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of BR112019002734A2 publication Critical patent/BR112019002734A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção refere-se a composições e métodos para a prevenção, tratamento e/ou cura funcional de infecção por hiv. um aspecto da presente invenção refere-se a anticorpos monoclonais direcionados contra cd4, composições dos mesmos e métodos empregando tais composições para a prevenção, tratamento e cura funcional de infecção por hiv.
BR112019002734-3A 2016-08-13 2017-08-13 tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart BR112019002734A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374752P 2016-08-13 2016-08-13
US62/374,752 2016-08-13
PCT/US2017/046668 WO2018035001A1 (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Publications (1)

Publication Number Publication Date
BR112019002734A2 true BR112019002734A2 (pt) 2019-05-14

Family

ID=61197201

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002734-3A BR112019002734A2 (pt) 2016-08-13 2017-08-13 tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart

Country Status (14)

Country Link
US (1) US11292839B2 (pt)
EP (1) EP3497133A4 (pt)
JP (1) JP2019534891A (pt)
KR (1) KR20190071677A (pt)
CN (1) CN109996815A (pt)
AU (1) AU2017312887A1 (pt)
BR (1) BR112019002734A2 (pt)
CA (1) CA3033728A1 (pt)
MX (1) MX2019001814A (pt)
RU (1) RU2019106804A (pt)
SG (2) SG10202100268RA (pt)
TW (1) TW201808998A (pt)
WO (1) WO2018035001A1 (pt)
ZA (1) ZA201901374B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001814A (es) * 2016-08-13 2019-07-08 Ubi Ip Holdings Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
US20220265711A1 (en) * 2019-05-16 2022-08-25 Nanjing Legend Biotech Co., Ltd. Engineered immune cells comprising a recognition molecule
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
JPH05505112A (ja) 1990-11-27 1993-08-05 バイオジェン，インコーポレイテッド Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
EP0746613B1 (en) 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
KR20010043797A (ko) 1998-05-25 2001-05-25 아사히 메디칼 가부시키가이샤 세포 분리 장치 및 분리 방법
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
CO5160259A1 (es) 1999-03-02 2002-05-30 Schering Corp Interferon alfa pegilado en la terapia contra el hiv
ES2301716T3 (es) 2001-12-11 2008-07-01 Biotectid Gmbh Utilizacion de un ligando marcado con especificidad para la molecula de cd4 humana, para la preparacion de un agente de diagnostico destinado al analisis de modelos de migracion y/o distribucion de poblaciones de celulas.
JP2003327536A (ja) 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
RU2393873C2 (ru) 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
WO2006117586A1 (en) 2005-05-02 2006-11-09 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
US20090214569A1 (en) 2005-08-25 2009-08-27 Government Of The Us, As Represented By The Secretary, Dept. Of Health & Human Services Use of HIV envelope/CD4 complexes for the generation antibodies
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
WO2014039840A1 (en) 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
WO2014159940A1 (en) 2013-03-14 2014-10-02 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
AU2014269042A1 (en) * 2013-05-24 2015-12-03 Cooper Human Systems Llc Methods and compositions for treatment of HIV infection
JP6716544B2 (ja) 2014-09-16 2020-07-01 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 競合的ｈｉｖ侵入阻害を媒介するｃｄ４に対するモノクローナル抗体によるｈｉｖ感染の処置および機能的治癒
MX2019001814A (es) * 2016-08-13 2019-07-08 Ubi Ip Holdings Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.

Also Published As

Publication number Publication date
SG10202100268RA (en) 2021-02-25
RU2019106804A (ru) 2020-09-21
EP3497133A4 (en) 2020-03-25
MX2019001814A (es) 2019-07-08
CA3033728A1 (en) 2018-02-22
EP3497133A1 (en) 2019-06-19
KR20190071677A (ko) 2019-06-24
US20190194326A1 (en) 2019-06-27
CN109996815A (zh) 2019-07-09
JP2019534891A (ja) 2019-12-05
TW201808998A (zh) 2018-03-16
AU2017312887A1 (en) 2019-03-07
ZA201901374B (en) 2022-04-28
SG11201901203PA (en) 2019-03-28
WO2018035001A1 (en) 2018-02-22
US11292839B2 (en) 2022-04-05
RU2019106804A3 (pt) 2021-03-29

Similar Documents

Publication Publication Date Title
BR112019002734A2 (pt) tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
IN2013MU01749A (pt)
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EA201690372A1 (ru) Азапиридоновые соединения и их применение
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
BR112018072467A2 (pt) composições farmacêuticas com permeação aumentada
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
CL2018003383A1 (es) Proteínas f de prefusión del vrs estabilizadas.
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
EA201990988A1 (ru) Антитела против chikv и пути их применения
BR112016022214A2 (pt) rnase para uso no tratamento ou prevenção de infecções virais
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]